Company overview
Syndex Bio develops the proprietary mcPCR platform, which enables high-fidelity amplification of both DNA methylation patterns and genetic sequences, overcoming limitations of traditional PCR. This technology supports sensitive analysis of methylated DNA in clinical samples, particularly for non-invasive biopsies in early disease detection and cancer monitoring. Based in Cambridge, UK, the company recently raised $15.5M in seed funding to expand R&D and clinical applications.
Syndex Bio is listed in the NovaPharmaNews Supplier Hub as a Diagnostics & Testing partner serving United States & Americas. Core focus areas include mcpcr, dna methylation, pcr amplification, molecular diagnostics, biopharma tools.
Industry categories: Diagnostics & Testing. These tags help R&D, manufacturing, and procurement teams discover vendors aligned with their pipeline stage and compliance requirements.
Products and technologies associated with Syndex Bio include Diagnostic, Pcr — relevant for pharmaceutical discovery, process development, and GMP manufacturing workflows.
Structured facts
- Website
- https://www.syndex.bio
- Categories
- Diagnostics & Testing
- Markets served
- United States & Americas
- Keywords
- mcpcr, dna methylation, pcr amplification, molecular diagnostics, biopharma tools
Products & technologies
Markets served
Industry categories
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Related suppliers in category
Frequently asked questions
- What is Syndex Bio's main technology offering?
- Syndex Bio's mcPCR platform preserves DNA methylation patterns during amplification, enabling PCR-like copying of both methylation marks and the four-base genetic code for high-sensitivity analysis.
- What applications does mcPCR support?
- mcPCR supports research and clinical workflows for analyzing methylated DNA in non-invasive and small-sample biopsies, aiding early disease detection, cancer recurrence monitoring, and molecular diagnostics.
- Where is Syndex Bio located and what is their funding status?
- Syndex Bio is based at Melbourn Science Park in Cambridge, UK, and raised an oversubscribed $15.5M seed round led by ARCH Venture Partners to expand the mcPCR platform and R&D.
Related editorial coverage
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
- AACR 2024: Oncology Research Highlights - Day 1 Roundup
- AACR 2026: AI Pathology & Oncolytic Virus Spark Interest
Explore lab tools and QA/QC resources for R&D teams.
